CHOKSI LABORATORIES LTD.

Choksi Laboratories Ltd has announced a change in its Registrar and Transfer Agent (RTA) from MUFG Intime India Private Limited to Ankit Consultancy Private Limited. This change, effective August 03, 2026, is due to a comprehensive evaluation of service offerings, technological capabilities, and local convenience. Electronic connectivity with NSDL and CDSL has been transferred accordingly. A tripartite agreement between the company, the outgoing RTA, and the incoming RTA will be executed shortly.

Choksi Laboratories Ltd has announced the closure of its trading window for all designated persons, their immediate relatives, and connected persons. The window will be closed effective July 1, 2026, until 48 hours after the declaration of the Unaudited Financial Results for the quarter ended June 30, 2026. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and related circulars. The company has also confirmed compliance with SEBI circulars regarding freezing PAN at the security level for restricting trading by designated persons. The exact date for the board meeting to approve the financial results will be communicated later.

Choksi Laboratories Ltd. has announced its audited financial results for the fourth quarter and financial year ended March 31, 2026. The results, approved by the Audit Committee and Board of Directors on May 25, 2026, show revenue from operations of ₹1288.41 lakhs. The audit report, conducted by Prateek Jain & Co., Chartered Accountants, expresses an unmodified opinion on the financial results, stating they present a true and fair view in accordance with applicable accounting standards.

Choksi Laboratories Ltd considered and approved the audited financial results for the quarter and financial year ended March 31, 2026, along with the auditor's report. The board meeting, held on May 25, 2026, also approved the Annual Secretarial Compliance Report for the year ended March 31, 2025. The trading window, which was closed on April 1, 2026, will remain closed until 48 hours after the declaration of the audited financial results.

Choksi Laboratories Ltd clarified that there was no delay in disclosing the resignation of Mr. Vyangesh Choksi as Chief Financial Officer, which was effective May 18, 2026. The company addressed BSE's inquiry regarding additional details for the corporate announcement filed under Regulation 30. The board also appointed Mrs. Stela Choksi as the new CFO and considered purchasing a car with loan facilities and changing the Registrar and Share Transfer Agent.

Choksi Laboratories Ltd has appointed Mrs. Stela Choksi as the Chief Financial Officer (CFO) effective May 18, 2026, following a board meeting. The appointment was recommended by the Audit and Nomination & Remuneration Committee. Mrs. Choksi is authorized to determine the materiality of events and make disclosures to stock exchanges. She is related to other directors: Mr. Sunil Choksi (Husband), Ms. Himika Choksi (Daughter), and Mr. Vyangesh Choksi (Son).

Mr. Vyangesh Choksi has resigned from his position as Chief Financial Officer (CFO) of Choksi Laboratories Ltd, effective from the close of business hours on May 18, 2026. He will continue to serve as the Whole Time Director of the company. The resignation was tendered on May 5, 2026, and taken on record on May 18, 2026, during a board meeting. The reason for his resignation is his commitment to ongoing multiple new projects within the company.

The Board of Directors of Choksi Laboratories Ltd, in a meeting held on May 18, 2026, approved the purchase of a 1 MG Windsor car with loan facilities from HDFC Bank. They also approved initiating the process to change the Registrar and Share Transfer Agent from MUFG Intime India Private Limited to Ankit Consultancy Private Limited. Mrs. Stela Choksi was appointed as the Chief Financial Officer, succeeding Mr. Vyangesh Choksi, who resigned. Other routine business matters were also addressed during the meeting, which lasted from 2:30 P.M. to 3:30 P.M.

Choksi Laboratories Ltd has scheduled a Board of Directors meeting on May 25, 2026, to consider and approve the standalone audited financial results for the fourth quarter and year ended March 31, 2026. The trading window, which was closed on April 1, 2026, will reopen 48 hours after the declaration of the audited financial results.

Choksi Laboratories Ltd has scheduled a Board of Directors meeting on May 18, 2026, to consider and approve several key items. These include the purchase of a car for business purposes and related credit facilities, a change of Registrar and Share Transfer Agent (RTA), and the appointment of a new Chief Financial Officer (CFO). The meeting will also address any other business items with the Chairman's permission and the consent of a majority of the directors, including at least one independent director.